Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress
Analyst Rating: Michael Okunewitch of Maxim Group maintains a Buy rating on Kiora Pharmaceuticals (KPRX) with a price target of $27.00, citing the company's strong financial position and promising drug development, particularly for its lead asset KIO-301 aimed at restoring vision in retinal disease patients.
Company Overview: Kiora Pharmaceuticals is a clinical stage specialty pharmaceutical company focused on eye diseases, with sufficient funding to support its operations until 2027 and a strategic partnership with Laboratoires Théa enhancing its commercial prospects.
Trade with 70% Backtested Accuracy
Analyst Views on KPRX
About KPRX
About the author
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Kiora Pharmaceuticals Joins RARE-X Vision Consortium: Kiora Pharmaceuticals has partnered with Global Genes to join the RARE-X Vision Consortium, aimed at enhancing collaboration among stakeholders to develop therapies for rare ocular disorders.
Goals of the Vision Consortium: The consortium focuses on patient identification, recruitment, and developing meaningful outcome measures for clinical trials, while integrating patient voices into study designs to improve the lives of those affected by rare vision disorders.
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
